YorkBridge Wealth Partners LLC trimmed its position in CVS Health Corp (NYSE:CVS) by 9.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,436 shares of the pharmacy operator’s stock after selling 249 shares during the quarter. YorkBridge Wealth Partners LLC’s holdings in CVS Health were worth $160,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the company. Vista Investment Management raised its stake in shares of CVS Health by 46.7% in the fourth quarter. Vista Investment Management now owns 7,230 shares of the pharmacy operator’s stock worth $474,000 after purchasing an additional 2,300 shares during the last quarter. National Pension Service grew its holdings in CVS Health by 36.2% during the fourth quarter. National Pension Service now owns 1,261,873 shares of the pharmacy operator’s stock worth $85,416,000 after acquiring an additional 335,312 shares during the period. PVG Asset Management Corp grew its holdings in CVS Health by 35.6% during the fourth quarter. PVG Asset Management Corp now owns 43,843 shares of the pharmacy operator’s stock worth $2,872,000 after acquiring an additional 11,507 shares during the period. Capital Financial Planning LLC acquired a new stake in CVS Health during the fourth quarter worth about $44,000. Finally, Colony Group LLC grew its holdings in CVS Health by 9.1% during the fourth quarter. Colony Group LLC now owns 16,028 shares of the pharmacy operator’s stock worth $1,050,000 after acquiring an additional 1,342 shares during the period. Hedge funds and other institutional investors own 81.55% of the company’s stock.
Shares of CVS opened at $52.63 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.65 and a debt-to-equity ratio of 1.22. CVS Health Corp has a 12 month low of $51.77 and a 12 month high of $82.15. The company has a market capitalization of $68.34 billion, a price-to-earnings ratio of 7.43, a price-to-earnings-growth ratio of 1.03 and a beta of 0.94.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 3rd. Shareholders of record on Tuesday, April 23rd will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 3.80%. The ex-dividend date of this dividend is Monday, April 22nd. CVS Health’s payout ratio is currently 28.25%.
In other CVS Health news, Director David W. Dorman acquired 9,600 shares of the company’s stock in a transaction on Friday, March 8th. The shares were bought at an average cost of $52.71 per share, with a total value of $506,016.00. Following the completion of the acquisition, the director now owns 122,302 shares in the company, valued at $6,446,538.42. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP James David Clark sold 1,664 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $58.14, for a total value of $96,744.96. Following the completion of the sale, the senior vice president now directly owns 8,557 shares in the company, valued at $497,503.98. The disclosure for this sale can be found here. Over the last three months, insiders acquired 23,600 shares of company stock worth $1,270,896 and sold 245,671 shares worth $15,839,966. 0.53% of the stock is currently owned by company insiders.
CVS has been the topic of several analyst reports. SunTrust Banks dropped their target price on CVS Health from $85.00 to $65.00 in a report on Wednesday, April 10th. UBS Group initiated coverage on CVS Health in a report on Thursday, January 17th. They set a “buy” rating and a $75.00 target price on the stock. Cantor Fitzgerald reaffirmed a “buy” rating and set a $96.00 target price on shares of CVS Health in a report on Thursday, January 3rd. Bank of America reaffirmed a “buy” rating and set a $92.00 target price on shares of CVS Health in a report on Thursday, January 3rd. Finally, Morgan Stanley set a $92.00 target price on CVS Health and gave the stock a “buy” rating in a report on Friday, February 22nd. One analyst has rated the stock with a sell rating, five have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $79.15.
ILLEGAL ACTIVITY NOTICE: This article was reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.baseballdailydigest.com/news/2019/04/21/cvs-health-corp-cvs-shares-sold-by-yorkbridge-wealth-partners-llc.html.
CVS Health Company Profile
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
See Also: What is a capital gain?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.